world-biomarkers-pharma-biotech-2017-posters

20 / 61

Notes:
Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 76
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
Cancer stem cells as the target: Early detection for therapy
Paola B Castro Garcia
University of Guadalajara, Mexico
Gliomas, like other types of cancer, are composed of a heterogeneous mixture of neoplastic cells, the great diversity between
tumor cells, makes them the center for different studies in vitro and in vivo for their ability to grow, an intimately related
property with the differentiation state of the cell. However there are cells that do not differentiate, regularly in a quiescent
state, which are called cancer stem cells (CSC`s) with great tumorigenic potential due to the ability of self-renewal that is
characteristic of a stem cell. Their proliferation by external stimuli or their own niche, gives rise to the offspring of multiple
lineages, among them to progenitors that later differentiate to a more specific cell. These quiescent cells can be a fundamental
therapeutic target, since currently cancer treatments are cytotoxic to most proliferating tumor cells, but do not destroy the
compartment of CSCs, allowing these cells to survive and give rise to tumor recurrence. However, the identity and origin of
CSCs remains unknown. In this paper we analyze the study of glioma cells and the implications of the CSC hypothesis for the
development of future therapies for brain tumors.
Biography
Paola B Castro Garcia has completed her PhD from Castilla-La Mancha University and Post-doctoral studies from Hokkaido University School of Medicine. She is
a Research Professor in University of Guadalajara, México.
Paola B Castro Garcia, J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-110